Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 1,904 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: AstraZeneca Clear all

Conditions: Influenza, Healthy
Interventions: Monovalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 3
States / cities: South Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD1222, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 32,450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 78
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more

Conditions: Advanced Solid Tumor
Interventions: DS-1103a, T-DXd; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 5
States / cities: Sarasota, Florida • New York, New York • Providence, Rhode Island + 2 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more

Conditions: Ovarian Cancer
Interventions: Durvalumab, BA3011, BA3021, ENB003, Toripalimab; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions: Eplontersen, ALXN2220, Placebo; Drug · Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 24
States / cities: La Jolla, California • San Francisco, California • Stanford, California + 21 more

Conditions: Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Interventions: D1400147, D14000136, D14000137, Epanova®; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Intracerebral Hemorrhage
Interventions: NXY-059; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 64
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 61 more

Conditions: Acute Myeloid Leukemia
Interventions: AZD1152, LDAC (low dose cytosine arabinoside); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 60 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Healthy
Interventions: AZD5099, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Chronic Lymphocytic Leukemia
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Fountain Valley, California • Redlands, California • Boca Raton, Florida + 13 more

Conditions: NSCLC
Interventions: Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 52
States / cities: Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 45 more

Conditions: Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers
Interventions: osimertinib, Bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Placebo, Tozorakimab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 57
States / cities: Birmingham, Alabama • Decatur, Alabama • Sheffield, Alabama + 51 more

Conditions: Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions: FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more

Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions: Acalabrutinib, Obinutuzumab, Venetoclax; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Supportive Care
Interventions: D-SCAN; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asymptomatic Hyperuricemia
Interventions: Verinurad, Febuxostat, Dapagliflozin, Dapagliflozin matched placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Ovarian Cancer
Interventions: olaparib, paclitaxel, carboplatin, Drug: carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 125 Years · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 8
States / cities: Stanford, California • West Hollywood, California • Orlando, Florida + 4 more

Conditions: Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: AZD9150, MEDI4736, AZD5069, tremelimumab (treme); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more

Conditions: Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
Interventions: Vandetanib, Capecitabine, Oxaliplatin, Bevacizumab; Drug
Lead sponsor: Branimir Sikic; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hidradenitis Suppurativa
Interventions: MEDI8968, Saline; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 27
States / cities: Phoenix, Arizona • Bakersfield, California • Fremont, California + 24 more

Conditions: Systemic Lupus Erythematosus
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Cary, North Carolina

Search by objective public record fields.

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects

MEOI and HRQoL in CLL Patients Treated With BTKis

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Dapagliflozin Patient Satisfaction Survey

Digital Supportive Care Awareness & Navigation

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Anifrolumab Pregnancy Study